Advice

following a full submission:

lenvatinib (Lenvima®) is accepted for use within NHSScotland.

Indication under review: As monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy.

In a phase III study in patients with unresectable hepatocellular carcinoma who had not received treatment for advanced disease, lenvatinib was non-inferior to another multikinase inhibitor for overall survival.

SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost effectiveness of lenvatinib and is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.

Medicine details

Medicine name:
lenvatinib (Lenvima)
SMC ID:
SMC2138
Indication:
as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy
Pharmaceutical company
Eisai Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Accepted
Date advice published:
08 April 2019